A role of histone H4 hypoacetylation in vascular endothelial growth factor expression in colon mucosa adjacent to implanted cancer in athymic mice cecum

Pathobiology

Volumn 70, Issue 6, 2002, Pages 348-352

  Kuniyasu, Hiroki ^a   Chihara, Yoshitomo ^a   Kondo, Hideaki ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Cancer host relationship; Colon cancer; Epigenetics; Histone acetylation; IL 15; Mucosal hyperplasia; TGF

Indexed keywords

CYTOKINE; EPIDERMAL GROWTH FACTOR; GROWTH FACTOR; HISTONE H4; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 15; PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

ACETYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER TRANSPLANTATION; CECUM; CELL LINE; COLON CANCER; COLON MUCOSA; CONTROLLED STUDY; DISEASE ASSOCIATION; EPITHELIUM CELL; GENE REPRESSION; HUMAN; HUMAN CELL; HYPERPLASIA; INTESTINE MUCOSA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT; UPREGULATION;

ACETYLATION; ANIMALS; CELL LINE, TUMOR; COLON; COLONIC NEOPLASMS; EPIDERMAL GROWTH FACTOR; EPIGENESIS, GENETIC; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HISTONES; HUMANS; HYPERPLASIA; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INTERLEUKIN-15; INTESTINAL MUCOSA; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; RATS; SPECIFIC PATHOGEN-FREE ORGANISMS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0038310270     PISSN: 10152008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000071275     Document Type: Article

References (35)

1. Mizzen CA, Allis CD: Linking histone acetylation to transcriptional regulation. Cell Mol Life Sci 1998;54:6-20.
2. Loidl P: Histone acetylation: Facts and questions. Chromosoma 1994;103:441-449.
3. Berger SL: Histone modifications in transcriptional regulation. Curr Opin Genet Dev 2002;12:142-148.
4. Peterson CL: HDAC's at work: Everyone doing their part. Mol Cell 2002;9:921-922.
5. Fax P, Lehmkuhler O, Kuhn C, Esche H, Brockmann D: E1A12S-mediated activation of the adenovirus type 12 E2 promoter depends on the histone acetyltransferase activity of p300/CBP. J Biol Chem 2000;275:40554-40560.
6. Marzio G, Giacca M: Chromatin control of HIV-1 gene expression. Genetica 1999;106:125-130.
7. Jenuwein T, Allis CD: Translating the histone code. Science 2001;293:1074-1080.
8. Cheung P, Allis CD, Sassone-Corsi P: Signaling to chromatin through histone modifications. Cell 2000;103:263-271.
9. Cheung P, Tanner KG, Cheung WL, Sassone-Corsi P, Denu JM, Allis CD: Synergistic coupling of histone H3 phosphorylation and acetylation in response to epidermal growth factor stimulation. Mol Cell 2000;5:905-915.
10. Sugimura T, Ushijima T: Genetic and epigenetic alterations in carcinogenesis. Mutat Res 2000;462:235-246.
11. Yasui W, Yokozaki H, Fujimoto J, Naka K, Kuniyasu H, Tahara E: Genetic and epigenetic alterations in multistep carcinogenesis of the stomach. J Gastroenterol 2000;35(suppl 12):111-115.
12. Nakao M: Epigenetics: Interaction of DNA methylation and chromatin. Gene 2001;278:25-31.
13. Gasser SM, Paro R, Stewart F, Aasland R: The genetics of epigenetics. Cell Mol Life Sci 1998;54:1-5.
14. Suzuki T, Yokozaki H, Kuniyasu H, Hayashi K, Naka K, Ono S, Ishikawa T, Tahara E, Yasui W: Effect of trichostatin A on cell growth and expression of cell cycle- and apoptosis-related molecules in human gastric and oral carcinoma cell lines. Int J Cancer 2000;88:992-997.
15. Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, Lee SW, Moon EJ, Kim HS, Lee SK, Chung HY, Kim CW, Kim KW: Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 2001;7:437-443.
16. 2 sensing. Science 2001;292:464-468.
17. Kuniyasu H, Yasui W, Shinohara H, Yano S, Ellis LM, Wilson MR, Bucana CD, Rikita T, Tahara E, Fidler IJ: Induction of angiogenesis by hyperplastic colonic mucosa adjacent to colon cancer. Am J Pathol 2000;157:1523-1535.
18. Greaves P, Filipe MI, Branfoot AC: Transitional mucosa and survival in human colorectal cancer. Cancer 1980;46:764-770.
19. Morikawa K, Walker SM, Jessup M, Fidler IJ: In vitro selection of highly metastatic cells from surgical specimens of different primary human colon carcinomas implanted into nude mice. Cancer Res 1988;48:1943-1948.
20. Morikawa K, Walker SM, Nakajima M, Pathak S, Jessup JM, Fidler IJ: Influence of organ environment on the growth, selection, and metastasis of human colon carcinoma cells in nude mice. Cancer Res 1988;48:6863-6871.
21. Fidler IJ: Orthotopic implantation of human colon carcinomas into nude mice provides a valuable model for the biology and therapy of metastasis. Cancer Metastasis Rev 1991;10:229-243.
22. Kuniyasu H, Oue N, Nakae D, Tsutsumi M, Denda A, Tsujiuchi T, Yokozaki H, Yasui W: Interleukin-15 expression is associated with malignant potential in colon cancer cells. Pathobiology 2001;69:86-95.
23. Ferrara N: Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res 2000;55:15-35.
24. Fidler IJ: Critical determinants of human colon cancer metastasis; in Tahara E (ed): Molecular Pathology of Gastroenterological Cancer. Tokyo, Springer, 1997, pp 147-169.
25. Ito M, Yoshida K, Kyo E, Ayhan A, Nakayama H, Yasui W, Ito H, Tahara E: Expression of several growth factors and their receptor genes in human colon carcinomas. Virchows Arch B Cell Pathol Incl Mol Pathol 1990;59:173-178.
26. Perrotte P, Matsumoto T, Inoue K, Kuniyasu H, Eve BY, Hicklin DJ, Radinsky R, Dinney CP: Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 1999;5:257-265.
27. Carson WE, Giri JG, Lindemann MJ, Linett ML, Ahdieh M, Paxton R, Anderson D, Eisenmann J, Grabstein K, Caligiuri MA: Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 1994;180:1395-1403.
28. Podolsky DK: Healing the epithelium: Solving the problem from two sides. J Gastroenterol 1997;32:122-126.
29. Gray SG, Svechnikova I, Hartmann W, O'Connor L, Aguilar-Santelises M, Ekstrom TJ: IGF-II and IL-2 act synergistically to alter HDAC1 expression following treatments with trichostatin a. Cytokine 2000;12:1104-1109.
30. Huang LE, Pete EA, Schau M, Milligan J, Gu J: Leu-574 of HIF-1α is essential for the von Hippel-Lindau (VHL)-mediated degradation pathway. J Biol Chem 2002;277:41750-41755.
31. Maxwell PH, Pugh CW, Ratcliffe PJ: The pVHL-hIF-1 system. A key mediator of oxygen homeostasis. Adv Exp Med Biol 2001;502:365-376.
32. Tsuzuki Y, Fukumura D, Oosthuyse B, Koike C, Carmeliet P, Jain RK: Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1alpha→ hypoxia response element→ VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Res 2000;60:6248-6252.
33. Hoeckel M, Vaupel P: Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;93:266-276.
34. Giatromanolaki A, Harris AL: Tumour hypoxia, hypoxia signaling pathways and hypoxia inducible factor expression in human cancer. Anticancer Res 2001;21:4317-4324.
35. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL: HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001;21:3995-4004.